Abstract:Pleomorphic adenoma is the most common benign tumor of the salivary glands tumors. First line treatment for this tumor is surgical excision and adjuvant radiotherapy was reported being applied to recurrent pleomorphic adenoma with high risk of recurrence. The aim of this study was to discuss the safety and treatment efficacy of (125) I seed interstitial brachytherapy for recurrent pleomorphic adenoma and propose the method to solve the clinical difficulty. Patients with recurrent pleomorphic adenoma of head and neck were included if the tumor cannot achieve complete resection with high risk of facial paralysis or high incidence of recurrence after operation. Patients were excluded if the tumor can achieve completely resection, risk and quality of life after surgery can be accepted, the patient had other malignant tumor history or were medically inoperable. The patients were performed CT and MRI used to develop the (125) I brachytherapy Plan in brachytherapy treatment planning system. The planning target volume (PTV) margin was designed matching the tumor margin. With 3D printing Individual template, CT or surgical navigation system guidance (125) I seed implantation was performed. Post-operation CT used to develop quality verification. The matched peripheral dose (MPD) was ranging from 110 to 140Gy. CT, MRI and biopsy were applied to evaluate treatment efficacy. From June 2012 to October 2015, 12 patients with recurrent pleomorphic adenoma were treated with (125) I seed brachytherapy alone (12 patients) or combined with surgery (1 patients), with follow-up ranging from 6 to 40 months (median, 15 months). Primary site of 13 patients was all parotid gland. Recurrent site of 8 patients were parotid gland while 3 were buccal and 2 were skull base. Patients accepted previous surgery from 1 to 4 times (median, 2.6 times) and 9 of 13 patients presented multinodular recurrence. 6 patients (50%) with 140Gy MPD reached complete response and 6 patients (50%) with 110∼120Gy MPD reached partial response in the 12 brachytherapy alone patients. The 6 patients also reached complete response 6 months after receiving the second time brachytherapy while nodules less than 1cm were all regression after the first time brachytherapy. 1 patient with adjuvant brachytherapy was no sign of tumor. 13 patients were locally controlled and facial nerve function was all preserved. No severe toxicities were observed. Preliminary results of this study showed 125I seed interstitial brachytherapy for recurrent pleomorphic adenoma presented excellent treatment efficacy which provided a safe and minimally invasive method avoiding the risk of facial paralysis brought by reoperation. Planning target volume and prescription dose could be optimized based on clinical and pathological features of recurrent pleomorphic adenoma and the size of tumor. Radiobiology and dosimetry problems about low-dose-rate brachytherapy for recurrent pleomorphic adenoma need further research.

Mandibular Growth in Pediatric and Adolescent Survivors of Parotid Gland Cancer Treated with Interstitial Brachytherapy

Mandibular Growth in Survivors of Pediatric Parotid Gland Carcinoma Treated with Interstitial Brachytherapy

Target volume determination of postoperative 125I seeds interstitial brachytherapy in parotid gland carcinoma

Primary Result of Early Parotid Gland Carcinomas with Optimized Target Design Brachytherapy

The Role of 125 I Interstitial Brachytherapy for Inoperable Parotid Gland Carcinoma

Iodine-125 Brachytherapy Alone for Advanced Primary Parotid Gland Carcinoma.

Application of 125I interstitial brachytherapy in the treatment of local advanced parotid adenoid cystic carcinoma

Target delineation and dosimetry analysis of 125I interstitial brachytherapy for recurrent adenoid cystic carcinoma in the parotid gland

Preliminary Results of (125)I Interstitial Brachytherapy for Locally Recurrent Parotid Gland Cancer in Previously Irradiated Patients.

Surgery Combined with Iodine-125 Interstitial Brachytherapy for Treatment of Parotid Adenoid Cystic Carcinoma: A Single-Institution Experience.

125I Seed Implant Brachytherapy for the Treatment of Unresectable Parotid Gland Malignant Tumours in Children

Efficacy of Surgery Combined with Postoperative 125 I Interstitial Brachytherapy for Treatment of Acinic Cell Carcinoma of the Parotid Gland in Children and Adolescents.

Clinicopathologic Analysis Of Oral Squamous Cell Carcinoma After I-125 Interstitial Brachytherapy

Clinical analysis of 125Ⅰ brachytherapy alone for 24 recurrent parotid gland carcinoma

Application of radioactive particle interstitial implant brachytherapy in the treatment of malignant adenogenous tumors invaded into cranial base area

(125)I Seed Interstitial Brachytherapy for Recurrent Pleomorphic Adenoma

The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy

Long-term Result of 125 I Seed Brachytherapy for Pediatric Desmoid Tumor in the Head and Neck

Radioactivity Seeds Interstitial Brachtherapy Treating Malignant Salivary Gland Tumors

Conservative parotidectomy combined with brachytherapy for parotid gland carcinoma

Surgery Combined with 125I Brachytherapy for Treatment of Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland